Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Eli Lilly's Business Segments
Eli Lilly's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 19,799
Regions Reported
2
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 19,799 | 100% |
Revenue Share by Region - Q1 FY2026
- Europe18.4%
- Rest of world14%
Revenue by Geographic Region - Q1 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Europe | $ 3,646 | 18.4% |
| Rest of world | $ 2,771 | 14% |
Revenue by Product & Service Category - Q1 FY2026
- Product93.2%
- Cardiometabolic Health50.1%
- Mounjaro21.4%
- Zepbound20.9%
- Collaboration and other revenue6.8%
- Oncology6.2%
- Verzenio3.6%
- Immunology3.1%
- Trulicity3%
- Other oncology2.6%
- Jardiance2.6%
- Other cardiometabolic health2.3%
- Taltz2.1%
- Neuroscience1.5%
- Other immunology1%
- Product and Service, Other0.3%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 18,453 | 93.2% |
| Cardiometabolic Health | $ 9,924 | 50.1% |
| Mounjaro | $ 4,232 | 21.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
13 more categories available
Sign in to unlock the full Eli Lilly dataset.
Description of Eli Lilly
Eli Lilly and Company, founded in 1876, is a global leader in the pharmaceutical industry, renowned for its dedication to discovering, developing, manufacturing, and marketing innovative pharmaceutical products aimed at addressing important unmet medical needs. With its origins tied closely to a commitment to improving the lives of patients, Eli Lilly has built a robust portfolio of medications that cover a wide array of therapeutic areas, including diabetes care, oncology, immunology, neurodegenerative diseases, and more.
Key Business Segments
Pharmaceutical Products
Eli Lilly operates primarily in the pharmaceutical sector, which constitutes the bulk of its business activities. The company invests heavily in research and development (R&D), allowing it to cultivate a strong pipeline of new therapies. R&D efforts have led to the introduction of novel drugs that have reshaped treatment paradigms for several diseases.
Animal Health Products
While Eli Lilly also maintains an animal health segment, it is not significant enough to materially impact the company’s overall financial performance. This division includes products designed for the prevention and treatment of diseases in domestic and agricultural animals, acknowledging the importance of animal welfare and livestock health in the broader context of public health.
Global Operations
Eli Lillys manufacturing and distribution capabilities extend beyond the United States to multiple international locations, including Puerto Rico and 17 other countries. The company operates several state-of-the-art facilities that adhere to stringent quality control measures and regulatory standards. This expansive operational footprint enables Eli Lilly to meet the demands of a global market, with its products being sold in approximately 140 countries worldwide.
Product Portfolio
Eli Lillys product offerings are extensive, featuring multiple blockbuster medications that have become staples in their respective markets. Some key therapeutic areas include:
- Diabetes Care: Eli Lilly is a pioneer in diabetes treatment, with well-known insulins such as Humalog and newer therapies like Trulicity, which offers innovative administration routes that enhance patient compliance.
- Oncology: The company has made significant strides in cancer treatment, with products like Verzenio for breast cancer and Alimta for lung cancer, among others, contributing to improved patient outcomes.
- Immunology: Eli Lilly’s contributions to immunology include therapies for rheumatoid arthritis and atopic dermatitis, using advanced mechanisms of action to provide relief for patients dealing with chronic autoimmune conditions.
- Neurodegenerative Diseases: Eli Lilly is active in developing treatments for diseases like Alzheimers, with ongoing research into therapies intended to slow disease progression and improve quality of life.
Commitment to R&D
Eli Lilly is recognized for its unwavering commitment to R&D, dedicating a substantial portion of its revenue to the discovery of new pharmaceutical products. The company collaborates with various research institutions, universities, and industry partners to leverage insights and accelerate drug development processes. This focus on innovation not only supports its existing product lines but also aims to anticipate future healthcare needs.
Market Impact and Strategy
Eli Lillys strategic orientation is characterized by a focus on specialized and targeted therapies that are developed using precision medicine principles. The company actively seeks to expand its portfolio through acquisitions, partnerships, and collaborations with biotech firms, aiming to access cutting-edge technologies and new treatment approaches.
Sustainability and Corporate Responsibility
In addition to its core business operations, Eli Lilly has made strides in corporate social responsibility and sustainability. The company is committed to minimizing its environmental footprint through sustainable manufacturing practices, waste reduction initiatives, and efforts to improve access to medications for underserved populations around the world.
Regulatory Compliance and Quality Assurance
Eli Lilly places a strong emphasis on compliance with regulatory standards set by authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Each phase of drug development, from clinical trials to post-market surveillance, is conducted under rigorous quality assurance protocols to ensure that products are safe and effective for patient use.
In summary, Eli Lilly and Company exemplifies a robust and innovative pharmaceutical enterprise, continually evolving to meet global healthcare challenges through its extensive product pipeline, commitment to R&D, and focus on delivering value to patients and healthcare professionals. The company is well-positioned to maintain its leadership role in the industry through its strategic initiatives and dedicated approach to pharmaceutical development.
Key Business Segments
Pharmaceutical Products
Eli Lilly operates primarily in the pharmaceutical sector, which constitutes the bulk of its business activities. The company invests heavily in research and development (R&D), allowing it to cultivate a strong pipeline of new therapies. R&D efforts have led to the introduction of novel drugs that have reshaped treatment paradigms for several diseases.
Animal Health Products
While Eli Lilly also maintains an animal health segment, it is not significant enough to materially impact the company’s overall financial performance. This division includes products designed for the prevention and treatment of diseases in domestic and agricultural animals, acknowledging the importance of animal welfare and livestock health in the broader context of public health.
Global Operations
Eli Lillys manufacturing and distribution capabilities extend beyond the United States to multiple international locations, including Puerto Rico and 17 other countries. The company operates several state-of-the-art facilities that adhere to stringent quality control measures and regulatory standards. This expansive operational footprint enables Eli Lilly to meet the demands of a global market, with its products being sold in approximately 140 countries worldwide.
Product Portfolio
Eli Lillys product offerings are extensive, featuring multiple blockbuster medications that have become staples in their respective markets. Some key therapeutic areas include:
- Diabetes Care: Eli Lilly is a pioneer in diabetes treatment, with well-known insulins such as Humalog and newer therapies like Trulicity, which offers innovative administration routes that enhance patient compliance.
- Oncology: The company has made significant strides in cancer treatment, with products like Verzenio for breast cancer and Alimta for lung cancer, among others, contributing to improved patient outcomes.
- Immunology: Eli Lilly’s contributions to immunology include therapies for rheumatoid arthritis and atopic dermatitis, using advanced mechanisms of action to provide relief for patients dealing with chronic autoimmune conditions.
- Neurodegenerative Diseases: Eli Lilly is active in developing treatments for diseases like Alzheimers, with ongoing research into therapies intended to slow disease progression and improve quality of life.
Commitment to R&D
Eli Lilly is recognized for its unwavering commitment to R&D, dedicating a substantial portion of its revenue to the discovery of new pharmaceutical products. The company collaborates with various research institutions, universities, and industry partners to leverage insights and accelerate drug development processes. This focus on innovation not only supports its existing product lines but also aims to anticipate future healthcare needs.
Market Impact and Strategy
Eli Lillys strategic orientation is characterized by a focus on specialized and targeted therapies that are developed using precision medicine principles. The company actively seeks to expand its portfolio through acquisitions, partnerships, and collaborations with biotech firms, aiming to access cutting-edge technologies and new treatment approaches.
Sustainability and Corporate Responsibility
In addition to its core business operations, Eli Lilly has made strides in corporate social responsibility and sustainability. The company is committed to minimizing its environmental footprint through sustainable manufacturing practices, waste reduction initiatives, and efforts to improve access to medications for underserved populations around the world.
Regulatory Compliance and Quality Assurance
Eli Lilly places a strong emphasis on compliance with regulatory standards set by authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Each phase of drug development, from clinical trials to post-market surveillance, is conducted under rigorous quality assurance protocols to ensure that products are safe and effective for patient use.
In summary, Eli Lilly and Company exemplifies a robust and innovative pharmaceutical enterprise, continually evolving to meet global healthcare challenges through its extensive product pipeline, commitment to R&D, and focus on delivering value to patients and healthcare professionals. The company is well-positioned to maintain its leadership role in the industry through its strategic initiatives and dedicated approach to pharmaceutical development.
Eli Lilly and Company is a global leader in the pharmaceutical industry, providing a diverse range of products and services across multiple therapeutic segments. Below is a detailed overview of the company’s primary segments, products, and services:
1. Neuroscience
Eli Lillys neuroscience division is central to its portfolio, featuring a range of medications designed to address mental health and neurological disorders:
- Zyprexa® (olanzapine): An antipsychotic medication used for the treatment of schizophrenia, acute manic episodes of bipolar disorder, and maintenance therapy for bipolar disorder.
- Prozac® (fluoxetine): An antidepressant belonging to the selective serotonin reuptake inhibitor (SSRI) class, indicated for major depressive disorder, bulimia nervosa, and obsessive-compulsive disorder (OCD).
- Strattera® (atomoxetine): A non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD), approved for use in children, adolescents, and adults.
- Permax® (pergolide): Primarily used in the management of Parkinsons disease to alleviate symptoms associated with the disorder.
- Sarafem® (fluoxetine): Specifically indicated for the treatment of premenstrual dysphoric disorder (PMDD), leveraging the same active ingredient as Prozac.
- Symbyax®: A combination of olanzapine and fluoxetine, this medication is indicated for treatment-resistant depression and bipolar depression.
- Darvon®: A line of analgesic products aimed at providing pain relief, primarily for mild to moderate discomfort.
Endocrine
Eli Lilly has a robust portfolio catering to diabetes management, growth hormone deficiencies, and bone health:
- Humulin®: A series of human insulin products synthesized through recombinant DNA technology, featuring various formulations for blood glucose management in diabetes.
- Humalog® (insulin lispro): A rapid-acting insulin analog designed for effective diabetes management, particularly for controlling postprandial blood glucose levels.
- Actos® (pioglitazone): Co-promoted with Takeda, this medication is used to treat Type 2 diabetes and is part of the thiazolidinedione drug class.
- Evista® (raloxifene): A selective estrogen receptor modulator (SERM) indicated for the prevention and treatment of osteoporosis in post-menopausal women.
- Humatrope® (somatropin): A synthetic growth hormone used for treating growth hormone deficiency in children and adults.
- Forteo® (teriparatide): A biologically active form of parathyroid hormone used for osteoporosis management in men and post-menopausal women at high risk for fractures.
Oncology
Eli Lillys oncology pipeline features several innovative therapies aimed at treating various cancer types:
- Gemzar® (gemcitabine): Utilized in the treatment of pancreatic cancer and for combination therapy in non-small-cell lung cancer.
- Alimta® (pemetrexed): Effective against malignant pleural mesothelioma and non-small-cell lung cancer, known for its specific action against tumors.
Animal Health
Eli Lilly extends its expertise into animal health, providing vital products for livestock and poultry management:
- Tylan® (tylosin): An antibiotic used to treat specific diseases affecting cattle, swine, and poultry.
- Rumensin® (monensin): A feed additive that enhances feed efficiency in cattle and helps control coccidiosis.
- Coban®, Monteban®, and Maxiban®: These anticoccidial agents are effective in controlling coccidiosis in poultry.
- Micotil® (tilmicosin) and Pulmotil® (tylosin): Used for managing respiratory conditions in cattle and swine, respectively.
- Paylean® and Optaflexx®: Performance enhancers designed to improve leanness and growth rates in swine and cattle.
Cardiovascular Agents
Eli Lilly is committed to addressing cardiovascular diseases with a range of medications:
- ReoPro® (abciximab): A monoclonal antibody used as an antiplatelet agent indicated for use during percutaneous coronary intervention (PCI).
- Xigris® (drotrecogin alfa): A recombinant protein indicated for the treatment of severe sepsis in critically ill patients.
- Dobutrex® (dobutamine): Utilized in managing cardiac decompensation by enhancing cardiac output.
- Cynt®: An antihypertensive medication marketed outside the U.S. for managing high blood pressure.
Anti-Infectives
Eli Lillys anti-infective line includes a variety of medications targeting bacterial infections:
- Ceclor® (cefaclor), Keflex® (cephalexin), Keftab® (cephradine), and Lorabid® (loracarbef): A range of oral antibiotics effective against various bacterial infections.
- Vancocin® HCl (vancomycin): Indicated for severe staphylococcal infections, particularly effective against MRSA.
Other Pharmaceuticals
The portfolio includes various additional therapeutic agents across different health areas:
- Axid® (nizatidine): An anti-ulcer medication used for gastric and duodenal ulcers.
- Cialis® (tadalafil): Indicated for erectile dysfunction, marketed in collaboration with ICOS Corporation, this product has achieved substantial global sales.
Research and Development
Eli Lilly is deeply committed to research and development, focusing on advancing existing medications, exploring new drug candidates across all therapeutic areas, and investigating innovative treatment strategies. Continuous investment in R&D aims to discover novel therapies that can address unmet medical needs.
Digital Health Solutions
In recognizing the increasing role of technology in healthcare, Eli Lilly is emphasizing digital health solutions. This includes the development of mobile health applications and platforms designed to enhance patient adherence to therapies, support disease management, and improve overall health outcomes for patients.
This extensive portfolio demonstrates Eli Lilly and Companys dedication to addressing crucial medical needs across various therapeutic segments and its ongoing commitment to innovation in the pharmaceutical industry.
1. Neuroscience
Eli Lillys neuroscience division is central to its portfolio, featuring a range of medications designed to address mental health and neurological disorders:
- Zyprexa® (olanzapine): An antipsychotic medication used for the treatment of schizophrenia, acute manic episodes of bipolar disorder, and maintenance therapy for bipolar disorder.
- Prozac® (fluoxetine): An antidepressant belonging to the selective serotonin reuptake inhibitor (SSRI) class, indicated for major depressive disorder, bulimia nervosa, and obsessive-compulsive disorder (OCD).
- Strattera® (atomoxetine): A non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD), approved for use in children, adolescents, and adults.
- Permax® (pergolide): Primarily used in the management of Parkinsons disease to alleviate symptoms associated with the disorder.
- Sarafem® (fluoxetine): Specifically indicated for the treatment of premenstrual dysphoric disorder (PMDD), leveraging the same active ingredient as Prozac.
- Symbyax®: A combination of olanzapine and fluoxetine, this medication is indicated for treatment-resistant depression and bipolar depression.
- Darvon®: A line of analgesic products aimed at providing pain relief, primarily for mild to moderate discomfort.
Endocrine
Eli Lilly has a robust portfolio catering to diabetes management, growth hormone deficiencies, and bone health:
- Humulin®: A series of human insulin products synthesized through recombinant DNA technology, featuring various formulations for blood glucose management in diabetes.
- Humalog® (insulin lispro): A rapid-acting insulin analog designed for effective diabetes management, particularly for controlling postprandial blood glucose levels.
- Actos® (pioglitazone): Co-promoted with Takeda, this medication is used to treat Type 2 diabetes and is part of the thiazolidinedione drug class.
- Evista® (raloxifene): A selective estrogen receptor modulator (SERM) indicated for the prevention and treatment of osteoporosis in post-menopausal women.
- Humatrope® (somatropin): A synthetic growth hormone used for treating growth hormone deficiency in children and adults.
- Forteo® (teriparatide): A biologically active form of parathyroid hormone used for osteoporosis management in men and post-menopausal women at high risk for fractures.
Oncology
Eli Lillys oncology pipeline features several innovative therapies aimed at treating various cancer types:
- Gemzar® (gemcitabine): Utilized in the treatment of pancreatic cancer and for combination therapy in non-small-cell lung cancer.
- Alimta® (pemetrexed): Effective against malignant pleural mesothelioma and non-small-cell lung cancer, known for its specific action against tumors.
Animal Health
Eli Lilly extends its expertise into animal health, providing vital products for livestock and poultry management:
- Tylan® (tylosin): An antibiotic used to treat specific diseases affecting cattle, swine, and poultry.
- Rumensin® (monensin): A feed additive that enhances feed efficiency in cattle and helps control coccidiosis.
- Coban®, Monteban®, and Maxiban®: These anticoccidial agents are effective in controlling coccidiosis in poultry.
- Micotil® (tilmicosin) and Pulmotil® (tylosin): Used for managing respiratory conditions in cattle and swine, respectively.
- Paylean® and Optaflexx®: Performance enhancers designed to improve leanness and growth rates in swine and cattle.
Cardiovascular Agents
Eli Lilly is committed to addressing cardiovascular diseases with a range of medications:
- ReoPro® (abciximab): A monoclonal antibody used as an antiplatelet agent indicated for use during percutaneous coronary intervention (PCI).
- Xigris® (drotrecogin alfa): A recombinant protein indicated for the treatment of severe sepsis in critically ill patients.
- Dobutrex® (dobutamine): Utilized in managing cardiac decompensation by enhancing cardiac output.
- Cynt®: An antihypertensive medication marketed outside the U.S. for managing high blood pressure.
Anti-Infectives
Eli Lillys anti-infective line includes a variety of medications targeting bacterial infections:
- Ceclor® (cefaclor), Keflex® (cephalexin), Keftab® (cephradine), and Lorabid® (loracarbef): A range of oral antibiotics effective against various bacterial infections.
- Vancocin® HCl (vancomycin): Indicated for severe staphylococcal infections, particularly effective against MRSA.
Other Pharmaceuticals
The portfolio includes various additional therapeutic agents across different health areas:
- Axid® (nizatidine): An anti-ulcer medication used for gastric and duodenal ulcers.
- Cialis® (tadalafil): Indicated for erectile dysfunction, marketed in collaboration with ICOS Corporation, this product has achieved substantial global sales.
Research and Development
Eli Lilly is deeply committed to research and development, focusing on advancing existing medications, exploring new drug candidates across all therapeutic areas, and investigating innovative treatment strategies. Continuous investment in R&D aims to discover novel therapies that can address unmet medical needs.
Digital Health Solutions
In recognizing the increasing role of technology in healthcare, Eli Lilly is emphasizing digital health solutions. This includes the development of mobile health applications and platforms designed to enhance patient adherence to therapies, support disease management, and improve overall health outcomes for patients.
This extensive portfolio demonstrates Eli Lilly and Companys dedication to addressing crucial medical needs across various therapeutic segments and its ongoing commitment to innovation in the pharmaceutical industry.